Dr. Robert Taub
Dr. Robert Taub is an oncologist and hematologist and has a special interest in the diagnosis, clinical care, and investigations of patients with malignant mesothelioma. Dr. Taub earned his Bachelor of Arts degree from Yeshiva University in New York and continued his education to get his Medical Degree from Yale University. He completed his fellowship training at New England Medical Center in Boston, Massachusetts and received a PhD from London University in London, England. He has several board certifications including Internal Medicine, Hematology, Oncology, and Allergy-Immunology. The list of universities he has served at is exhaustive but includes the Assistant through Associate Professor of Medicine at Mount Sinai School of Medicine; Professor and Chairman of Medical Oncology, and American Cancer Society Professor of Clinical Oncology at the Medical College of Virginia. He has also served as Professor of Clinical Medicine and Co-Director at Columbia University Comprehensive Cancer Center. Currently he is working with the Columbia Mesothelioma Center.
Dr. Taub is interested in treating mesothelioma with a combination of radiation and chemotherapy. The Columbia Mesothelioma Center under the direction of Dr. Taub is working on techniques that use intracavitary chemotherapy for multimodal treatment of abdominal mesothelioma and for a treatment of pleural mesothelioma that could spare the lung.
Dr. Taub is a proponent of change in the surgical and chemotherapy treatments of patients with malignant pleural mesothelioma, His hope is that the use of a chemotherapy and radiation combination will directly target the lung’s lining and thus avoid surgery. It is also the hope of Dr. Taub, and others doing this research, that the radiation therapy will only kill cancer cells on the surface of the lung and spare other parts of the lung and other vital tissues that surround it. This radiation therapy will deliver radioactive isotope P-32 directly into the pleural cavity. Patients will also receive chemotherapy using the drugs cisplatin and doxorubicin through catheters. Some patients, randomly selected, will also receive systemic chemotherapy using cisplatin and pemetrexed. Any patient has the option of additional surgery to remove affected lung lining or the lung in whole. After initial treatment patients will also be offered outpatient systemic chemotherapy that uses cisplatin and pemetrexed.
- Columbia University Medical Center. Physician Profile.
Last modified: December 24, 2010.